Real-world outcomes associated with bevacizumab combined with chemotherapy in platinum-resistant ovarian cancer.

作者
Gordon Taylor Moffat,Weidong Kong,Christopher M. Booth,Josée-Lyne Ethier
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:40 (16_suppl): 5555-5555
标识
DOI:10.1200/jco.2022.40.16_suppl.5555
摘要

5555 Background: In the pivotal Aurelia study, addition of bevacizumab (bev) to physician’s choice chemotherapy (paclitaxel, liposomal doxorubicin or topotecan) for platinum-resistant (PL-R) ovarian cancer (OC) was associated with improved progression-free survival (PFS; 6.7 vs 3.4 mos; hazard ratio (HR) 0.48, p = 0.001) but not overall survival (OS; 16.6 vs 13.3 mos HR 0.85, p = 0.174); the latter finding may relate to extensive crossover. In an exploratory subgroup analysis by treatment arm, benefits were particularly marked for bev + paclitaxel where median PFS (mPFS) increased from 3.9 to 10.4 mos (HR 0.46; 95%CI 0.30-0.71) and increases in OS approached statistical significance (HR 0.65; 95%CI, 0.42-1.02; 22.4 v 13.2 mos). Here we describe utilization of bev for PL-R OC and outcomes in routine clinical practice. Methods: The Ontario Cancer Registry and the New Drug Funding Program databases were utilized to identify all patients treated with bev plus chemotherapy (paclitaxel, liposomal doxorubicin or topotecan) for PL-R OC following its approval in 2017. Time on treatment (ToT) was defined as time from first to last bev treatment; this was used as a surrogate for PFS in routine practice. Median OS (mOS) was determined using the Kaplan-Meier method. Factors associated with ToT and OS were identified using a Cox proportional hazard model. A before and after comparison analysis was performed to determine mOS for patients treated pre- (2011-2017) and post-bev (2017-2019) approval. Results: From Oct 2017 to Dec 2019, 180 patients received bev + chemotherapy for first-line PL-R OC. Mean age was 63 years old, and 80% had serous OC. Bev was most often combined with liposomal doxorubicin (64 %) followed by paclitaxel (34%) and topotecan (2%). Median ToT was 3 months and OS was 11 months. ToT and OS were longer in patients who received paclitaxel as chemotherapy backbone (5 mos [ToT]; 14 mos [OS]) than those who received bev with liposomal doxorubicin (2 mos; 9 mos) or topotecan (2 mos; 6 mos). In multivariable models, ToT was superior in patients who received bev + paclitaxel than bev + liposomal doxorubicin (HR 0.40; 95%CI 0.28-0.57; p < 0.0001), and worse with longer time from diagnosis to bev start (1.03; 1.01-1.05; p = 0.0120). OS was also significantly longer in those who received paclitaxel vs liposomal doxorubicin (HR 0.54; 95%CI 0.30-0.98; p = 0.043). In a before and after analysis, patients treated in the pre- (n = 1290) and post-bev (n = 360) era had mOS of 8 and 9 months respectively. Post mOS increased for patients receiving paclitaxel (7 vs 12 months) but not with liposomal doxorubicin (9 vs 7 months). Conclusions: ToT and OS associated with bev for PL-R OC are shorter in a real-world population compared to results reported in AURELIA. ToT and OS were longer with bev + paclitaxel than with other chemotherapy agents.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
XuanWayne完成签到,获得积分10
刚刚
ldz完成签到,获得积分20
刚刚
郷禦完成签到,获得积分10
刚刚
刚刚
投必快业必毕完成签到,获得积分10
刚刚
zzzz完成签到 ,获得积分10
刚刚
鞋子完成签到,获得积分10
刚刚
花菜完成签到 ,获得积分10
1秒前
嘻嘻哈哈的应助被qqqqqq采纳,获得30
1秒前
1秒前
水煮电吹风的应助被干饭啦采纳,获得10
1秒前
sun发布了新的文献求助10
1秒前
2秒前
yu完成签到,获得积分10
2秒前
xfy完成签到,获得积分10
2秒前
杜洋完成签到,获得积分10
2秒前
北极熊不吃火锅完成签到,获得积分10
2秒前
2026年我要发paper完成签到,获得积分10
3秒前
3秒前
清风徐来完成签到,获得积分10
3秒前
天天向上的应助被蜗牛采纳,获得10
3秒前
4秒前
4秒前
Alav0314完成签到,获得积分10
4秒前
carbonhan完成签到,获得积分10
4秒前
虾米完成签到,获得积分10
4秒前
扬帆起航完成签到,获得积分10
4秒前
Crazy鑫完成签到,获得积分10
4秒前
ccc完成签到,获得积分10
5秒前
爆米花的应助被文龙采纳,获得10
5秒前
桐桐的应助被躺赢的猴哥采纳,获得10
5秒前
墨清烟完成签到 ,获得积分10
5秒前
qn完成签到,获得积分10
5秒前
英俊的高跟鞋完成签到,获得积分10
5秒前
风禾尽起发布了新的文献求助10
6秒前
洁净的绿海完成签到 ,获得积分10
6秒前
HH发布了新的文献求助10
6秒前
钟少完成签到 ,获得积分10
6秒前
6秒前
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180407
求助须知:如何正确求助?哪些是违规求助? 9570403
关于积分的说明 21811831
捐赠科研通 7776452
什么是DOI,文献DOI怎么找? 3433277
关于科研通互助平台的介绍 2557499
邀请新用户注册赠送积分活动 2479105